{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:41:25Z","timestamp":1789879285919,"version":"4.0.1"},"reference-count":126,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There has been a major revolution in the management of patients with myeloproliferative neoplasms (MPN), and in particular those with myelofibrosis and extensive splenomegaly and symptomatic burden, after the introduction of the JAK1 and JAK2 inhibitor ruxolitinib. The drug also has been approved as second-line therapy for polycythemia vera (PV). However, the therapeutic armamentarium for MPN is still largely inadequate for coping with patients\u2019 major unmet needs, which include normalization of life span (myelofibrosis and some patients with PV), reduction of cardiovascular complications (mainly PV and essential thrombocythemia), prevention of hematological progression, and improved quality of life (all MPN). In fact, none of the available drugs has shown clear evidence of disease-modifying activity, even if some patients treated with interferon and ruxolitinib showed reduction of mutated allele burden, and ruxolitinib might extend survival of patients with higher-risk myelofibrosis. Raised awareness of the molecular abnormalities and cellular pathways involved in the pathogenesis of MPN is facilitating the development of clinical trials with novel target drugs, either alone or in combination with ruxolitinib. Although for most of these molecules a convincing preclinical rationale was provided, the results of early phase 1 and 2 clinical trials have been quite disappointing to date, and toxicities sometimes have been limiting. In this review, we critically illustrate the current landscape of novel therapies that are under evaluation for patients with MPN on the basis of current guidelines, patient risk stratification criteria, and previous experience, looking ahead to the chance of a cure for these disorders.<\/jats:p>","DOI":"10.1182\/blood-2016-10-695965","type":"journal-article","created":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T21:00:18Z","timestamp":1482872418000},"page":"693-703","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":83,"title":["Emerging treatments for classical myeloproliferative neoplasms"],"prefix":"10.1182","volume":"129","author":[{"given":"Alessandro M.","family":"Vannucchi","sequence":"first","affiliation":[{"name":"Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy\u2019s and St Thomas\u2019 National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2019111910452066400_B1","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"2019111910452066400_B2","first-page":"1284","article-title":"Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug","volume":"89","author":"Passamonti","year":"2004","journal-title":"Haematologica"},{"key":"2019111910452066400_B3","author":"Alvarez-Larr\u00e1n"},{"issue":"4","key":"2019111910452066400_B4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","article-title":"White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study","volume":"126","author":"Barbui","year":"2015","journal-title":"Blood"},{"issue":"29","key":"2019111910452066400_B5","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111910452066400_B6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111910452066400_B7","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111910452066400_B8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1846.1846","article-title":"Treatment of essential thrombocythemia in Europe: an observational study of 3649 high-risk patients in exels [abstract]","volume":"124","author":"Birgegard","year":"2014","journal-title":"Blood"},{"issue":"8102","key":"2019111910452066400_B9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","article-title":"Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia","volume":"2","author":"Pearson","year":"1978","journal-title":"Lancet"},{"issue":"1","key":"2019111910452066400_B10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111910452066400_B11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111910452066400_B12","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Haematologica"},{"key":"2019111910452066400_B13"},{"issue":"1","key":"2019111910452066400_B14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/leu.2014.250","article-title":"Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)","volume":"29","author":"Barosi","year":"2015","journal-title":"Leukemia"},{"issue":"13","key":"2019111910452066400_B15","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"24","key":"2019111910452066400_B16","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","article-title":"Improving survival trends in primary myelofibrosis: an international study","volume":"30","author":"Cervantes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111910452066400_B17","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"2019111910452066400_B18","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"15","key":"2019111910452066400_B19","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111910452066400_B20","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"2019111910452066400_B21","author":"Guglielmelli"},{"issue":"7","key":"2019111910452066400_B22","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111910452066400_B23","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2019111910452066400_B24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.13260","article-title":"A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients","volume":"169","author":"Wassie","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111910452066400_B25","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111910452066400_B26","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/sj.leu.2405080","article-title":"Choosing between stem cell therapy and drugs in myelofibrosis","volume":"22","author":"Kr\u00f6ger","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"2019111910452066400_B27","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/modpathol.2015.93","article-title":"Recombinant interferon-\u03b1 in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response","volume":"28","author":"Pizzi","year":"2015","journal-title":"Mod Pathol"},{"issue":"6","key":"2019111910452066400_B28","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.12459","article-title":"Efficacy and safety of pegylated-interferon \u03b1-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups","volume":"162","author":"Ianotto","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111910452066400_B29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3324\/haematol.2013.087650","article-title":"Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies","volume":"99","author":"Mesa","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"2019111910452066400_B30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111910452066400_B31","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111910452066400_B32","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2141.2005.05524.x","article-title":"Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients","volume":"129","author":"Cervantes","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111910452066400_B33","doi-asserted-by":"crossref","article-title":"How I treat myelofibrosis","author":"Cervantes","DOI":"10.1182\/blood-2014-07-575373"},{"issue":"7","key":"2019111910452066400_B34","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3324\/haematol.12416","article-title":"Low-dose thalidomide in myelofibrosis","volume":"93","author":"Weinkove","year":"2008","journal-title":"Haematologica"},{"issue":"8","key":"2019111910452066400_B35","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/sj.leu.2404711","article-title":"Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"issue":"27","key":"2019111910452066400_B36","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","article-title":"Pomalidomide is active in the treatment of anemia associated with myelofibrosis","volume":"27","author":"Tefferi","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111910452066400_B37","article-title":"A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence [published online ahead of print 18 November 2016]","author":"Tefferi","journal-title":"Leukemia"},{"issue":"9","key":"2019111910452066400_B38","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111910452066400_B39","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111910452066400_B40","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/14740338.2016.1185414","article-title":"Safety considerations when treating myelofibrosis","volume":"15","author":"O\u2019Sullivan","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"2019111910452066400_B41","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"2019111910452066400_B42","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","article-title":"Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts","volume":"123","author":"Passamonti","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2019111910452066400_B43","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","article-title":"Impact of mutational status on outmes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study","volume":"123","author":"Guglielmelli","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111910452066400_B44","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3892\/etm.2013.886","article-title":"Ruxolitinib for myelofibrosis","volume":"5","author":"Gu","year":"2013","journal-title":"Exp Ther Med"},{"issue":"12","key":"2019111910452066400_B45","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111910452066400_B46","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111910452066400_B47","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"issue":"13","key":"2019111910452066400_B48","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111910452066400_B49","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3324\/haematol.2013.095109","article-title":"Resolution of bone marrow fibrosis in a patient receiving JAK1\/JAK2 inhibitor treatment with ruxolitinib","volume":"98","author":"Wilkins","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"2019111910452066400_B50","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111910452066400_B51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.13379","article-title":"Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial","volume":"170","author":"Mead","year":"2015","journal-title":"Br J Haematol"},{"key":"2019111910452066400_B52","article-title":"Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib","author":"Davis"},{"issue":"9","key":"2019111910452066400_B53","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematologica"},{"key":"2019111910452066400_B54","author":"Passamonti"},{"issue":"7","key":"2019111910452066400_B55","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"2019111910452066400_B56","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ejh.12707","article-title":"Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy","volume":"97","author":"Mesa","year":"2016","journal-title":"Eur J Haematol"},{"issue":"17","key":"2019111910452066400_B57","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJMc1502524","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111910452066400_B58","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2015-01-624536","article-title":"JAK2V617F complete molecular remission in polycythemia vera\/essential thrombocythemia patients treated with ruxolitinib","volume":"125","author":"Pieri","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111910452066400_B59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","article-title":"Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia","volume":"152","author":"Hern\u00e1ndez-Boluda","year":"2011","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111910452066400_B60","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bjh.13886","article-title":"Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera","volume":"172","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111910452066400_B61","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1847.1847","article-title":"Long-term results from a phase II open-label study of ruxolitinib in patients with essential thrombocythemia refractory to or intolerant of hydroxyurea [abstract]","volume":"124","author":"Verstovsek","year":"2014","journal-title":"Blood"},{"key":"2019111910452066400_B62","author":"Harrison"},{"issue":"5","key":"2019111910452066400_B63","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"2019111910452066400_B64","article-title":"A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis [published online ahead of print 2 September 2016]","author":"Verstovsek","journal-title":"Leukemia"},{"issue":"21","key":"2019111910452066400_B65","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.714.714","article-title":"Primary analysis results from an open-label phase II study of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis [abstract]","volume":"124","author":"Mascarenhas","year":"2014","journal-title":"Blood"},{"key":"2019111910452066400_B66","author":"Mesa"},{"issue":"1","key":"2019111910452066400_B67","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3324\/haematol.2016.148924","article-title":"A phase 1\/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis","volume":"102","author":"Gupta","year":"2017","journal-title":"Haematologica"},{"key":"2019111910452066400_B68","article-title":"[abstract]","author":"Pardanani"},{"issue":"3","key":"2019111910452066400_B69","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/leu.2014.306","article-title":"Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis","volume":"29","author":"Pardanani","year":"2015","journal-title":"Leukemia"},{"issue":"23","key":"2019111910452066400_B70","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.824.824","article-title":"Safety and efficacy of combination therapy of interferon-alpha2 + JAK1-2 inhibitor in the Philadelphia-negative chronic myeloproliferative neoplasms. Preliminary results from the Danish Combi-Trial - an open label, single arm, non-randomized multicenter phase II study [abstract]","volume":"126","author":"Mikkelsen","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111910452066400_B71","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.823.823","article-title":"5-azacytidine (AZA) in combination with ruxolitinib (RUX) as therapy for patients (pts) with myelodysplastic\/myeloproliferative neoplasms (MDS\/MPNs) [abstract]","volume":"126","author":"Daver","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111910452066400_B72","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.825.825","article-title":"Phase 1b\/2 study of the efficacy and safety of Sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis [abstract]","volume":"126","author":"Gupta","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111910452066400_B73","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.826.826","article-title":"A phase-Ib\/II study of ruxolitinib plus pomalidomide in myelofibrosis [abstract]","volume":"126","author":"Stegelmann","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111910452066400_B74","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.827.827","article-title":"An open-label, multicenter, 2-arm, dose-finding, phase 1b study of the combination of ruxolitinib and buparlisib (BKM120) in patients with myelofibrosis: results from HARMONY study [abstract]","volume":"126","author":"Durrant","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111910452066400_B75","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1618.1618","article-title":"Final analysis of a multicenter pilot phase 2 study of ruxolitinib and danazol in patients with myelofibrosis [abstract]","volume":"126","author":"Gowin","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111910452066400_B76","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4060.4060","article-title":"Efficacy, safety, and confirmation of the recommended phase 2 starting dose of the combination of ruxolitinib (RUX) and panobinostat (PAN) in patients (pts) with myelofibrosis (MF) [abstract]","volume":"126","author":"Harrison","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111910452066400_B77","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/bjh.13046","article-title":"Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms","volume":"167","author":"Mwirigi","year":"2014","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111910452066400_B78","article-title":"Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by goelams-FIM in collaboration with the sfgmtc [abstract]","volume":"122","author":"Francois","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111910452066400_B79","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.exphem.2003.11.003","article-title":"Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera","volume":"32","author":"Ugo","year":"2004","journal-title":"Exp Hematol"},{"issue":"12","key":"2019111910452066400_B80","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.exphem.2009.09.009","article-title":"Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation","volume":"37","author":"Laubach","year":"2009","journal-title":"Exp Hematol"},{"issue":"4","key":"2019111910452066400_B81","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2141.2009.07870.x","article-title":"Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms","volume":"147","author":"Grimwade","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111910452066400_B82","doi-asserted-by":"crossref","first-page":"e54826","DOI":"10.1371\/journal.pone.0054826","article-title":"mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms","volume":"8","author":"Bogani","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"2019111910452066400_B83","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/jcmm.12162","article-title":"Co-targeting the PI3K\/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms","volume":"17","author":"Bartalucci","year":"2013","journal-title":"J Cell Mol Med"},{"issue":"5","key":"2019111910452066400_B84","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1535-7163.MCT-12-0862","article-title":"Dual PI3K\/AKT\/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells","volume":"12","author":"Fiskus","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"2019111910452066400_B85","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","article-title":"Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111910452066400_B86","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-05-0068","article-title":"Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor\/insulin receptor substrate-1\/phosphatidylinositol 3-kinase cascade","volume":"4","author":"Shi","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2019111910452066400_B87","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.leu.2402901","article-title":"In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia","volume":"17","author":"Mesa","year":"2003","journal-title":"Leukemia"},{"issue":"9","key":"2019111910452066400_B88","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/sj.leu.2404816","article-title":"A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia","volume":"21","author":"Mesa","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"2019111910452066400_B89","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00277-005-1104-7","article-title":"Treatment with valproic acid for myelofibrosis with myeloid metaplasia","volume":"84","author":"Inoue","year":"2005","journal-title":"Ann Hematol"},{"issue":"4","key":"2019111910452066400_B90","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bjh.12416","article-title":"A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia","volume":"162","author":"Andersen","year":"2013","journal-title":"Br J Haematol"},{"issue":"24","key":"2019111910452066400_B91","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","article-title":"Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111910452066400_B92","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjh.12220","article-title":"A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera\/essential thrombocythaemia myelofibrosis (post-PV\/ET MF)","volume":"161","author":"Mascarenhas","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111910452066400_B93","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.leu.2405049","article-title":"The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)","volume":"22","author":"Guerini","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"2019111910452066400_B94","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111910452066400_B95","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.12332","article-title":"A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy","volume":"161","author":"Finazzi","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111910452066400_B96","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.leukres.2012.03.003","article-title":"Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis","volume":"36","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Leuk Res"},{"issue":"3","key":"2019111910452066400_B97","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1046\/j.0007-1048.2001.03319.x","article-title":"Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation","volume":"116","author":"Wang","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111910452066400_B98","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.leukres.2004.11.002","article-title":"Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia","volume":"29","author":"Kumagai","year":"2005","journal-title":"Leuk Res"},{"issue":"1","key":"2019111910452066400_B99","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2141.2008.07541.x","article-title":"Decitabine is an effective treatment of idiopathic myelofibrosis","volume":"145","author":"Danilov","year":"2009","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111910452066400_B100","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.leukres.2010.05.008","article-title":"Therapeutic options for patients with myelofibrosis in blast phase","volume":"34","author":"Mascarenhas","year":"2010","journal-title":"Leuk Res"},{"issue":"2","key":"2019111910452066400_B101","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/10428194.2013.802315","article-title":"Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine","volume":"55","author":"Liu","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111910452066400_B102","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/leu.2008.91","article-title":"A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia\/polycythemia vera myelofibrosis","volume":"22","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Leukemia"},{"issue":"19","key":"2019111910452066400_B103","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","article-title":"Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)","volume":"116","author":"Thepot","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111910452066400_B104","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.leukres.2003.09.006","article-title":"Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases","volume":"28","author":"Bock","year":"2004","journal-title":"Leuk Res"},{"issue":"4","key":"2019111910452066400_B105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/jcp.2007.054353","article-title":"Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis","volume":"62","author":"Florena","year":"2009","journal-title":"J Clin Pathol"},{"issue":"10","key":"2019111910452066400_B106","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111910452066400_B107","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111910452066400_B108","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2012-06-439661","article-title":"Characterization of the TGF-\u03b21 signaling abnormalities in the Gata1low mouse model of myelofibrosis","volume":"121","author":"Zingariello","year":"2013","journal-title":"Blood"},{"issue":"13","key":"2019111910452066400_B109","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2014-01-547760","article-title":"Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms","volume":"123","author":"Bhagwat","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111910452066400_B110","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3109\/10428194.2014.984703","article-title":"Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis","volume":"56","author":"Sasaki","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111910452066400_B111","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-2141.2007.06885.x","article-title":"Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations","volume":"140","author":"Boveri","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111910452066400_B112","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3324\/haematol.2012.083337","article-title":"Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial","volume":"98","author":"Mesa","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"2019111910452066400_B113","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/leu.2008.32","article-title":"Bortezomib therapy in myelofibrosis: a phase II clinical trial","volume":"22","author":"Mesa","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"2019111910452066400_B114","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ajh.21754","article-title":"Phase I\/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition","volume":"85","author":"Barosi","year":"2010","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111910452066400_B115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3816\/CLML.2010.n.058","article-title":"Phase II study of sunitinib in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"10","author":"Apostolidou","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2019111910452066400_B116","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2008-06-158386","article-title":"Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence","volume":"112","author":"Lataillade","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2019111910452066400_B117","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1084\/jem.20160283","article-title":"Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis","volume":"213","author":"Verstovsek","year":"2016","journal-title":"J Exp Med"},{"issue":"2","key":"2019111910452066400_B118","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3109\/10428194.2013.805329","article-title":"Anti-transforming growth factor-\u03b2 therapy in patients with myelofibrosis","volume":"55","author":"Mascarenhas","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111910452066400_B119","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ajh.23409","article-title":"The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms","volume":"88","author":"Tadmor","year":"2013","journal-title":"Am J Hematol"},{"issue":"31","key":"2019111910452066400_B120","doi-asserted-by":"crossref","first-page":"27630","DOI":"10.1074\/jbc.M111.243113","article-title":"Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase","volume":"286","author":"Eliades","year":"2011","journal-title":"J Biol Chem"},{"issue":"6","key":"2019111910452066400_B121","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies","volume":"101","author":"Zahr","year":"2016","journal-title":"Haematologica"},{"issue":"6121","key":"2019111910452066400_B122","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"issue":"6121","key":"2019111910452066400_B123","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"issue":"3","key":"2019111910452066400_B124","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/mt.2014.226","article-title":"Efficient and allele-specific genome editing of disease loci in human iPSCs","volume":"23","author":"Smith","year":"2015","journal-title":"Mol Ther"},{"issue":"8","key":"2019111910452066400_B125","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2019111910452066400_B126","article-title":"Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: Findings from the MPN Landmark survey [published online ahead of print 30 September 2016]","author":"Mesa","journal-title":"Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/6\/693\/1401703\/blood695965.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/6\/693\/1401703\/blood695965.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T09:07:53Z","timestamp":1718960873000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/6\/693\/36312\/Emerging-treatments-for-classical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":126,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,2,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-10-695965","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,9]]}}}